ADLAI NORTYE LTD. - AMERICAN DEPOSITARY SHARES

Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025

10 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress

08 Aug 2024 08:30:00 By Nasdaq GlobeNewswire

Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors

08 Aug 2024 08:00:01 By Nasdaq GlobeNewswire

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

23 May 2024 21:03:04 By Nasdaq GlobeNewswire

Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

22 May 2024 08:00:00 By Nasdaq GlobeNewswire

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

29 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

17 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award

23 Oct 2023 08:12:53 By Nasdaq GlobeNewswire

Adlai Nortye Ltd. Announces Closing of Initial Public Offering

03 Oct 2023 12:05:08 By Nasdaq GlobeNewswire

Adlai Nortye Ltd. Announces Pricing of Initial Public Offering

29 Sep 2023 02:46:00 By Nasdaq GlobeNewswire